Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462187 · ClinicalTrials.gov registry record · Phase 2
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
A Phase 2 study of Genital Warts and Perianal Warts, sponsored by Novan.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 15
- Study locations
NCT02462187 is a Phase 2 study of Genital Warts and Perianal Warts that has completed, run by Novan. The registered enrollment target is 108 participants. The trial reports 15 study locations across 8 states.
The verdict
NCT02462187, a Phase 2 study of Genital Warts and Perianal Warts, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 15
- Study locations
Study Summary
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG NVN1000 8% Gel
- DRUG NVN1000 16%
- DRUG NVN1000 24%
Study Locations (15)
Texas
- PPD 128 - Corpus Christi
- PPD 129 - Houston
- PPD 127 - San Antonio
- PPD 131 - Webster
California
- PPD 137 - Fountain Valley
- PPD 140 - Lomita
- PPD 133 - San Diego
Georgia
- PPD 134 - Atlanta
- PPD 139 - Atlanta
- PPD 138 - Roswell
Indiana
- PPD 130 - Indianapolis
Louisiana
- PPD 126 - Metairie
Oregon
- PPD 132 - Portland
Pennsylvania
- PPD 135 - Philadelphia
Washington
- PPD 136 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-06-12 |
| Est. Completion | 2016-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02462187
The ClinicalTrials.gov registry entry for NCT02462187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Genital Warts appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT02462187 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02462187 about?
NCT02462187 is a clinical study titled "Topical NVN1000 for the Treatment of External Genital and Perianal Warts". A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
What is the current status of trial NCT02462187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2015-06-12. Estimated completion is 2016-10-17.
What conditions does trial NCT02462187 study?
This clinical trial studies the following conditions: Genital Warts, Perianal Warts.
What interventions are being tested in trial NCT02462187?
The interventions under investigation include: Vehicle (DRUG), NVN1000 8% Gel (DRUG), NVN1000 16% (DRUG), NVN1000 24% (DRUG).
Who is sponsoring clinical trial NCT02462187?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462187 being conducted?
This trial has 15 study locations across California, Georgia, Indiana, Louisiana, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.